NMN 125 mg appears on a real retail tablet label, including Jarrow’s NMN product. It identifies the amount of nicotinamide mononucleotide in the labeled tablet, not a universally established starting dose.
This lower amount can be easier to recognize than a multi-ingredient blend, but label simplicity does not establish effectiveness. The important question is whether the evidence being cited actually tested 125 mg in a comparable product and population.
125 mg is a real NMN tablet amount. It is not an established universal starter dose, and findings at 250 mg cannot simply be divided in half.
What the Jarrow label says
Jarrow’s public panel lists a serving size of one tablet containing 125 mg NMN, with 60 tablets in the bottle. Those facts describe the unit of purchase. They do not establish that every adult should use it or that the amount treats fatigue.
The Jarrow review considers the tablet as an NMN supplement. It should not be compared with an injection by treating the number on each label as the same type of dose.
Why one tablet is not always one serving elsewhere
NOVOS Boost illustrates the need to read both lines of a label: its two-capsule serving supplies 250 mg NMN. An individual capsule therefore represents a different fraction of that product’s labeled serving than Jarrow’s single tablet.
This is label arithmetic, not advice to alter either product’s directions. It explains why capsule count, tablet count, and total milligrams need to remain separate in a shopping comparison.
A 250 mg study is not a 125 mg result
A randomized trial in 30 healthy adults tested 250 mg NMN daily for 12 weeks and reported an increase in whole-blood NAD. It did not test Jarrow’s 125 mg tablet as the intervention.
You cannot halve the studied amount and assume either half the effect or the same effect. The 250 mg evidence guide describes the research more closely, including why a biomarker finding is not a demonstrated longevity benefit.
Lower does not automatically mean suitable
A smaller labeled amount may be relevant to a conversation about a supplement, but it cannot answer medication-interaction, medical-history, or pregnancy questions on its own. Bring the actual label and your other products to a qualified clinician or pharmacist when deciding whether to use it.
Avoid a self-directed escalation plan based on whether an immediate sensation occurs. Feeling nothing does not identify a biological deficiency or a correct next amount.
How to compare a 125 mg product fairly
Record the molecule, amount per labeled serving, servings per bottle, other ingredients, and price for the selected purchase type. Compare that with another NMN product rather than a direct-NAD or NR bottle.
For readers choosing between precursor categories, NMN versus NR provides a more meaningful starting point than sorting every NAD-related product from the smallest milligram number to the largest.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Jarrow Formulas: NMN 125 mg Manufacturer lists 60 tablets and one-tablet serving; suggested use also permits two tablets, changing bottle duration. Checked September 18, 2026.
- NOVOS: Boost NMN Manufacturer explicitly distinguishes NMN ingredient research from trials of the finished Boost product. Checked September 18, 2026.
- Okabe et al. (2022): 250 mg NMN trial Thirty healthy adults, 250 mg NMN or placebo for 12 weeks. Whole-blood NAD and short-term observations; not a finished-product endorsement.
- FDA: questions and answers on dietary supplements Regulatory categories and limits of premarket review.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.